The significance of the work lies in what it replaces. Virtually all industrial fermentation that yields nitrogen-rich products, from amino acids to nucleotides, depends on ammonium salts or urea as the nitrogen feedstock, and those inputs trace back to Haber–Bosch ammonia synthesis. That process, which combines atmospheric nitrogen with hydrogen under extreme pressures and temperatures, consumes an estimated one to two percent of global energy output and generates substantial carbon dioxide emissions as a byproduct of hydrogen production from natural gas. Biological nitrogen fixation, carried out by the nitrogenase enzyme complex in certain bacteria and archaea, performs the same chemical transformation at ambient temperature and pressure using ATP and electrons, offering a potentially far gentler route to usable nitrogen.

Azotobacter vinelandii has long served as the model organism for aerobic nitrogen fixation, a biologically awkward combination since oxygen both damages nitrogenase and competes for the electrons the enzyme needs. The bacterium survives this paradox through extraordinarily high respiratory rates that consume oxygen before it can reach the enzyme. Previous efforts had engineered A. vinelandii to excrete ammonium, the natural next step after nitrogen fixation, since the fixed nitrogen normally feeds the cell’s own biosynthesis. But the researchers behind the new study found that studies on actually using that excreted ammonium as a nitrogen source for other microbes remained limited, and that ammonium production levels were too low to be industrially interesting.

To push yields higher, the team took aim at NifA, the transcriptional activator that switches on the entire nif regulon encoding the nitrogen fixation machinery. They constructed A. vinelandii strains by integrating a nifA overexpression cassette, driven by the strong tac promoter, into the algU locus of the chromosome. This chromosomal integration strategy matters for stability: rather than relying on a plasmid that could be lost during cultivation, the engineered construct is inherited by every daughter cell, ensuring the nitrogen fixation program stays dialed up throughout a fermentation run. The resulting strain stably produced ammonium at a concentration of 1 gram per liter in simple flask cultures, a level the researchers describe as a solid baseline for the platform.

Flask cultures, however, are a proving ground rather than a production environment. The team then scaled the process into a jar fermenter, where they could control oxygen transfer, pH and feeding with far greater precision. By combining fed-batch cultivation, in which fresh carbon source is supplied incrementally to avoid depletion or overflow metabolism, with antifoam treatment to keep the aerated broth from foaming over and lactic acid addition to manage the culture’s chemistry, they raised ammonium production to 1.5 grams per liter. Each of these process interventions addresses a practical bottleneck: fed-batch keeps the energy supply matched to the nitrogenase’s enormous ATP appetite, antifoam protects oxygen transfer and prevents contamination pathways, and acid addition stabilizes the pH as ammonium accumulates and shifts the broth’s acid-base balance.

With a reliable ammonium source in hand, the researchers turned to the second half of the partnership. Corynebacterium glutamicum is arguably the most successful amino acid production organism in industrial biotechnology, responsible for the bulk of the world’s several-million-ton annual L-glutamate output, the flavor-enhancing component of monosodium glutamate. In the co-culture scheme, the engineered A. vinelandii functions as a living nitrogen fertilizer, continuously fixing atmospheric nitrogen gas and releasing ammonium into the shared medium, while C. glutamicum assimilates that ammonium and channels it through its existing metabolic machinery into L-glutamate. The division of labor elegantly sidesteps the need to purify or concentrate the intermediate: the product of one microbe is the substrate of the other, delivered in situ.

The results demonstrated the concept convincingly. Co-cultivation of the ammonium-producing A. vinelandii strain with C. glutamicum enabled the production of 2 grams per liter of L-glutamate from nitrogen gas. While that titer remains well below the tens of grams per liter achieved in conventional glutamate fermentations fed with commercial ammonium, the demonstration establishes a complete biological pipeline from atmospheric dinitrogen to a finished amino acid in a single vessel. The researchers frame the strategy as a contribution to the development of environment-friendly fermentation processes for producing various nitrogen-containing compounds from nitrogen gas, suggesting the platform could extend well beyond glutamate to other amino acids, nucleotides and nitrogenous chemicals.

The engineering choices embedded in the study reveal a careful reading of nitrogenase regulation. NifA sits atop a hierarchy of control mechanisms that bacteria use to avoid wasting energy on nitrogen fixation when fixed nitrogen is already available, a regulatory logic that normally shuts the system down precisely when engineers want it running. By overexpressing NifA from a constitutive tac promoter, the team effectively overrides the ammonium-sensing feedback that would otherwise silence the nif genes as product accumulates. Placing the cassette at the algU locus, which governs stress responses in A. vinelandii, reflects a deliberate choice of a neutral genomic landing site that disrupts native function minimally while granting stable, high-level expression of the activator.

Scaling challenges remain before such co-cultures could challenge conventional plants. Nitrogenase is an enzyme of notorious fragility and metabolic cost, demanding roughly sixteen ATP per molecule of nitrogen reduced, and maintaining two microbial populations with different physiological optima in one fermenter requires balancing oxygen availability, carbon source preference and growth rates. The fed-batch jar fermenter results, with their combination of antifoam and lactic acid management, hint at the kind of process engineering refinement that will determine whether titers can climb toward commercial relevance. The involvement of Kikkoman Corporation, a company with deep roots in fermentation technology, alongside academic groups at The University of Tokyo’s Department of Biotechnology and Collaborative Research Institute for Innovative Microbiology, suggests industrial interest in closing that gap. Several of the authors have filed patent applications on the work, underscoring its perceived commercial potential.

For now, the study stands as a proof of concept with a compelling narrative: a flavor compound that seasons much of the world’s food, assembled in part from the air itself, by two bacteria cooperating in a fermenter. If the platform’s titers can be improved through further strain and process optimization, nitrogen-fixing co-cultures could offer fermentation industries a route to decouple amino acid production from synthetic fertilizer inputs, trimming both energy demand and carbon emissions. The researchers position their work as a step toward fermentation processes that draw their nitrogen directly from the atmosphere, converting a century-old industrial dependency into a biological partnership.

Subject of Research: L-glutamate production from nitrogen gas via co-culture of engineered Azotobacter vinelandii and Corynebacterium glutamicum

Article Title: L-Glutamate production from nitrogen gas by co-culturing Corynebacterium glutamicum with Azotobacter vinelandii

Article References: Ito, Y., Yoshidome, D., Araki, Y., Ito, K., Hidaka, M., Kosono, S., & Nishiyama, M. (2026). L-Glutamate production from nitrogen gas by co-culturing Corynebacterium glutamicum with Azotobacter vinelandii. Applied Microbiology and Biotechnology. https://doi.org/10.1007/s00253-026-14031-5

Image Credits: AI Generated

DOI: 10.1007/s00253-026-14031-5

Keywords: Azotobacter vinelandii, Corynebacterium glutamicum, nitrogen fixation, L-glutamate, co-culture, nifA overexpression, ammonium production, Haber-Bosch, metabolic engineering, fed-batch fermentation, nitrogenase, sustainable biotechnology

The trouble with conventional tools is well documented. Two-dimensional cell cultures, such as the widely used B16F10 mouse melanoma line, are accessible and highly pigmented but do not capture the molecular heterogeneity of human disease. Human melanoma lines like the Sk-Mel series, MNT-1, and A375 offer more relevant genetics but remain simplified. Primary melanocytes isolated from skin biopsies behave more like cells in the body but survive only a limited number of passages before senescence. Animal models—mice, zebrafish, the frog Xenopus laevis, guinea pigs, swine, chick embryos, and fruit flies—each bring valuable features, from the optical clarity of zebrafish embryos to the tyrosinase-dependent, MITF-independent melanin deposition in Xenopus, but they suffer from divergent protein–protein interactions, species-specific genetics, high costs, and mounting ethical constraints. Most critically, identical visible pigmentation phenotypes in humans can arise from entirely distinct molecular disruptions, a depth of heterogeneity that flat cultures and cross-species models frequently miss, leading to inconsistent and unpredictable therapeutic responses.

The review, published in Bioengineering & Translational Medicine, organizes the emerging alternative into three converging categories unified by the iterative Design-Build-Test-Learn engineering cycle. The first is classical synthetic biology: direct genetic and metabolic rewiring using tools such as CRISPR-Cas9, TALENs, and heterologous microbial expression. CRISPR-Cas9, adapted from a bacterial immune system, uses a guide RNA to direct the Cas9 endonuclease to a precise DNA target, where the resulting break is repaired by non-homologous end joining or homology-directed repair. Researchers have exploited this to build exquisitely controlled disease models: knocking out SIRT1 in murine melanoma cells suppresses melanogenesis by reducing MITF expression through altered p38 and ERK signaling, creating a hypopigmentation model relevant to vitiligo, whereas ablating SIRT7 upregulates melanin production via MITF and its downstream enzymes, mimicking melasma and lentigines. In a striking proof of concept, CRISPR was used to correct the T373K missense mutation that abolishes tyrosinase activity in oculocutaneous albinism, restoring enzyme function and melanin content in an animal model and establishing a precise genotype-to-phenotype platform with implications for somatic gene therapy.

Delivery remains the central obstacle to translating these edits into clinic-ready treatments, because the stratum corneum aggressively blocks large molecular cargos and viral vectors carry limited capacity and immunogenic risks. Recent bioengineering work points toward non-viral solutions. A polyamine-modified thermosensitive hydrogel, liquid at refrigerator temperature but gelling at body temperature, has successfully delivered CRISPR-Cas9 ribonucleoproteins through the skin, achieving a 46 percent gene mutation frequency in vivo with no systemic toxicity. Complementary ex vivo strategies—correcting a patient’s own skin cells in the laboratory, expanding them as epidermal sheets, and grafting them back—offer a path to durable, safety-validated gene correction for genetic skin disorders. TALENs, which pair a DNA-binding domain with a FokI nuclease, add a second editing option with lower off-target risk, as demonstrated by disrupting the slc24a5 gene in tuna to produce hypopigmentation.

The second category, heterologous expression systems, swaps slow mammalian kinetics for engineered microbes, transforming melanin from a scarce biological product into an industrially manufacturable biomaterial. The standout example is the marine bacterium Vibrio natriegens, which doubles roughly every ten minutes; when engineered to express a prokaryotic tyrosinase from Bacillus megaterium and supplemented with L-tyrosine and copper, it generates visible melanin within fifteen minutes and saturates the culture within two hours. The same platform demonstrated optogenetic control, using blue light to derepress tyrosinase expression with reversible, spatially precise timing. Parallel efforts in Escherichia coli express tyrosinases such as melA from Rhizobium etli or route flux through the hppd gene to produce pyomelanin, while modular co-expression of multiple enzymes yields non-natural variants like melanin-diamine complexes optimized for fabric dyeing. Eukaryotic hosts fill the gap where post-translational modification matters: the yeast Yarrowia lipolytica secretes pyomelanin with photoprotective and antioxidant properties suitable for dermatological formulations, retaining the glycosylation machinery that bacteria lack.

The third and physiologically richest category comprises biomimetic systems that recreate the dynamic microenvironment of living skin. Co-culturing primary melanocytes and keratinocytes from vitiligo patients produces a patient-specific platform whose drug responses differ markedly from healthy controls—resistant to melanogenic stimulators and hypersensitive to inhibitors—making it a predictive preclinical proxy. Three-dimensional melanocyte spheroids rescue the melanin production that flat monolayers lose, and when treated with the skin-lightening compound fucoxanthin they outperform commercial tissue equivalents in sensitivity. Perhaps most impressive are microfluidic skin-on-a-chip devices: one bilayer-hydrogel platform, perfused with circulating 17β-estradiol and tuned oxygen gradients, reproduces the exact hyperpigmentation patterns of pregnancy-induced melasma, demonstrating that hormone-driven disorders can now be modeled outside the body. Skin explants preserved in gravity-driven, pumpless chips maintain viability for clinical monitoring and personalized testing.

At the macroscopic end of the spectrum, 3D bioprinting and reconstructed human pigmented skin (RHPS) and epidermis (RHPE) models bring structural fidelity to high-throughput screening. Printed bioinks containing live cells and gelatin-alginate matrices are cross-linked, cultured submerged, and then shifted to an air-liquid interface, where exposure to air forces keratinocytes to differentiate and stratify into a viable, keratinized epidermis. Commercial systems such as MelanoDerm, EpiSkin, SkinEthic, and EpiDerm, built from melanocytes and keratinocytes of diverse genetic ancestries, already support safety testing accepted by regulators for dermal irritation and phototoxicity under New Approach Methodologies aligned with the 3Rs of animal research. Pushing to the sub-cellular scale, researchers have engineered artificial melanosomes—tyrosinase encapsulated in lipid vesicles or polymersomes—that synthesize melanin only when triggered by ultraviolet light or that migrate to the perinuclear region of keratinocytes, mimicking the DNA-shielding nuclear caps of native melanosomes. Stem cell technologies extend the vision toward regenerative medicine, with induced pluripotent stem cell–derived melanocytes and MUSE cells integrating into the basal layer of skin organoids without tumorigenic risk.

Complementing all of these live systems are cell-free assays that strip melanogenesis down to its isolated biochemistry. Simple tyrosinase assays using L-DOPA remain a gold standard for rapid inhibitor screening, and they delivered a definitive mechanistic answer in the case of plumbagin, confirming it as a direct enzymatic inhibitor rather than an upstream regulator. More advanced transcription-translation (TXTL) systems can synthesize melanogenic proteins entirely outside living cells, sidestepping host toxicity and metabolic competition. These reductionist platforms are exceptionally reproducible but deliberately blind to membrane permeability and cellular feedback loops, so their findings must be validated in more complex biomimetic models. Emerging cell-free regenerative approaches—platelet-rich plasma, extracellular vesicles, and stem cell secretomes—may bypass transplantation risks altogether by stimulating resident melanocyte precursors and countering oxidative stress in disorders such as vitiligo.

The review is candid about remaining gaps. Engineered microbes are scalable but poorly represent human melanocyte biology; biomimetic constructs are physiologically faithful but expensive, hard to standardize, and still lack immune, vascular, and neural components. CRISPR faces off-target effects, immune recognition of bacterial Cas9, and delivery challenges in continuously renewing skin, prompting development of high-fidelity variants and anti-CRISPR safeguards. Engineered live therapeutics fall under strict regulatory oversight, and industrial melanin production demands biosafety containment and genetic safeguards against environmental release. Yet the trajectory is clear: by unifying programmable gene circuits, engineered microbes, printed tissue, organ-on-chip microenvironments, and synthetic organelles under shared engineering principles, researchers are replacing unpredictable and ethically constrained models with controllable biosystems. The payoff spans next-generation diagnostics, targeted therapies for vitiligo and melasma, biologically integrated sunscreens, antioxidant delivery vehicles, melanin-based radiometal sorbents for nuclear medicine, and even organic semiconductors—a breadth that positions engineered pigmentation platforms as one of the most versatile toolkits in modern dermatology.

Subject of Research: Engineered synthetic biology and biomimetic platforms for studying melanogenesis and pigmentation disorders

Article Title: Engineered platforms for melanogenesis research: Bridging synthetic biology, bioengineering, and biomimetics

Article References: Engineered platforms for melanogenesis research: Bridging synthetic biology, bioengineering, and biomimetics. (n.d.). https://doi.org/10.1002/btm2.70159

Image Credits: AI Generated

DOI: 10.1002/btm2.70159

Keywords: melanogenesis, melanin, synthetic biology, CRISPR-Cas9, biomimetics, 3D bioprinting, skin-on-a-chip, artificial melanosomes, heterologous expression, vitiligo, melasma, reconstructed human skin

Synthetic consortia represent an emerging frontier in biotechnology, and their appeal lies in the principle of division of labor. Rather than cramming every metabolic function into a single organism, researchers can distribute tasks across specialized members, each optimized for its role. This approach reduces the metabolic burden on any one cell, improves robustness, and, according to the authors, offers a reduced risk of contamination because the engineered partners occupy the ecological niche that invaders would otherwise exploit. Consortia that combine phototrophic and heterotrophic bacteria are especially attractive because the phototrophic partner can harvest light energy and fix atmospheric CO2, effectively converting an abundant greenhouse gas into organic carbon that sustains the rest of the community.

Most previous explorations of such phototrophic–heterotrophic partnerships have relied on sucrose as the transferred carbon source. Sucrose, however, is a relatively large molecule, and its export and import require dedicated transport machinery. Acetate offers a simpler alternative. It is a small two-carbon compound produced naturally as a by-product by many microorganisms, including the model cyanobacterium Synechocystis PCC 6803, the workhorse of cyanobacterial synthetic biology. The catch is that wild-type cyanobacteria secrete only trace amounts of acetate during phototrophic growth—far too little to support a productive industrial partnership.

The Uppsala team solved this problem in earlier work through targeted metabolic engineering. By introducing a phosphoketolase, or PK, an enzyme that reroutes carbon flux through the central carbon metabolism of the cyanobacterium, and by overexpressing phosphotransacetylase, or Pta, the enzyme that channels acetyl-phosphate toward acetate, they created a high-producing strain designated WT_PKPa_RBS_BsPta_Δacs. The acs deletion prevents re-assimilation of secreted acetate, locking the cell into an export phenotype. The resulting organism secretes significant levels of acetate into its growth medium, turning it into a living, sunlight-powered carbon factory.

With the acetate donor in hand, the next challenge was to build reliable consumers. Roussou and Lindblad engineered two different heterotrophs for 1-butanol production: Escherichia coli, the standard bacterium of metabolic engineering, and Pseudomonas taiwanensis, a robust soil-dwelling species increasingly favored for its tolerance of harsh conditions. Both strains were first cultivated on acetate as their sole carbon source, demonstrating that they could grow on the very molecule the engineered cyanobacterium produces. Only after this critical validation were the partners combined.

The researchers then established two distinct synthetic consortia, pairing the acetate-secreting Synechocystis strain individually with each of the butanol-producing heterotrophs. Remarkably, the co-cultures were maintained for 42 days, an extended duration that speaks to the stability of the engineered partnerships. Throughout the experiment, the team successfully monitored growth dynamics, tracking how each member of the community fared over more than a month of continuous co-existence under phototrophic conditions.

The measurements told a coherent story. Acetate concentrations in the consortia were lower than in a corresponding axenic Synechocystis culture, a difference that indicates the heterotrophic partners were actively consuming the carbon being secreted by the cyanobacteria. In other words, the engineered phototroph was not merely dumping acetate into the medium; it was feeding its partners. Crucially, 1-butanol was detected in both co-cultures, confirming that the transferred photosynthetic carbon was being converted into the desired end product by the engineered E. coli and P. taiwanensis strains.

This demonstration is conceptually important because it closes a loop that many in the field have tried to close. Photosynthetic microbes can fix CO2 with sunlight, but they are often inefficient producers of complex chemicals. Heterotrophic microbes are superb synthetic chemists but need organic feedstocks, which typically come from plant biomass or sugar in conventional biorefineries. By coupling the two through acetate, the study shows that a renewable, food-independent supply chain is technically feasible: sunlight and CO2 in, acetate out of one organism, and 1-butanol out of another, all within a single co-culture vessel.

1-Butanol itself is a compelling target. It is a four-carbon alcohol with fuel properties closer to gasoline than ethanol, making it attractive as a drop-in biofuel or blending component, and it also serves as a precursor for paints, coatings, polymers, and solvents. Industrial production currently relies on petrochemical routes or on traditional Clostridium fermentations that require sugar feedstocks and suffer from solvent toxicity to the producing organism. Outsourcing butanol synthesis to heterotrophs fed by a photosynthetic partner could, in principle, decouple production from agricultural inputs while the cyanobacterium simultaneously captures CO2.

The work, funded by the European Union’s Horizon 2020 research and innovation program under the PROMICON project, also carries practical lessons for the broader synthetic ecology community. Maintaining a stable consortium for six weeks shows that carefully matched production and consumption rates can keep the partnership in balance, and the detectable butanol titers in both pairings suggest the acetate channel is robust across different heterotrophic chassis. Challenges remain before such systems approach industrial relevance, including raising acetate secretion rates, improving butanol titers and tolerance, and scaling photobioreactor conditions. Yet the study establishes a clear proof of principle: photosynthetically derived acetate can sustain heterotrophic production of a value-added bulk chemical in a designed microbial community, charting a path toward sunlight-driven biomanufacturing built on cooperation rather than a single overloaded cell.

Subject of Research: Synthetic phototrophic-heterotrophic bacterial consortia engineered to convert photosynthetically derived acetate into 1-butanol

Article Title: Synthetic consortia towards photosynthetically derived acetate for heterotrophic production of 1-butanol

Article References: Roussou, S., & Lindblad, P. (2026). Synthetic consortia towards photosynthetically derived acetate for heterotrophic production of 1-butanol. Applied Microbiology and Biotechnology, 110(1), Article 268. https://doi.org/10.1007/s00253-026-14029-z

Image Credits: AI Generated

DOI: 10.1007/s00253-026-14029-z

Keywords: synthetic consortia, Synechocystis PCC 6803, Escherichia coli, Pseudomonas taiwanensis, acetate, 1-butanol, cyanobacteria, metabolic engineering, synthetic biology, CO2 fixation, biofuels, phototrophic-heterotrophic co-culture

A study published in Nature Sustainability by Yinuo Liu, Yingxin Zhao and colleagues at Tianjin University now reports a strikingly elegant solution to this bottleneck, one that reads almost like science fiction. Instead of adding chemicals or redesigning reactors, the team used a 3D bioprinter to fabricate engineered living materials, or ELMs, in which anammox bacteria and their denitrifying partners are locked together in a precisely printed microarchitecture. Within these printed living structures, the microbes exchange metabolites so efficiently that the system achieved complete nitrogen removal, eliminating one hundred percent of nitrogen from the water, and did so without any external supply of organic carbon. When the researchers validated the approach with real wastewater, the performance held.

The core insight behind the work is fundamentally ecological rather than purely technological. Anammox bacteria, often abbreviated AnAOB, are notoriously slow growers with doubling times measured in days or even weeks, and they naturally produce nitrate as a byproduct of their metabolism. In an ideal system, denitrifying bacteria living alongside them would consume that nitrate, reducing it further to nitrogen gas and closing the nitrogen loop. This cross-feeding partnership exists in nature, but in conventional bioreactors it is fragile. Metabolites drift away in the flowing water before partner organisms can capture them, and the physical distance between anammox cells and denitrifiers dilutes the chemical conversation the two groups need to hold. The result is nitrate piling up in the effluent and treatment performance falling short of what the biology should theoretically allow.

The Tianjin team’s answer was to give the microbial community an architecture. They formulated a bioink composed of sodium alginate and cellulose, two abundant and biocompatible natural polymers, and loaded it with a concentrated anammox consortium. Using extrusion-based 3D printing, they deposited this living ink into defined three-dimensional structures that combine two properties that are usually difficult to reconcile: mechanical stability to survive the harsh conditions of a wastewater reactor, and an open, porous microstructure that lets water and substrates flow through while keeping the cells densely packed inside. The printed materials function simultaneously as scaffolds, as microbial incubators and as diffusion barriers that trap metabolites close to the cells that produce them.

Spatial confinement proved to be the decisive factor. Inside the printed ELMs, cell densities reached levels far higher than those achievable in suspended cultures, forcing microbial cells into intimate proximity. That proximity activated synergistic metabolic pathways that remained dormant or marginal in free-floating consortia. Using metagenomic and metabolomic analyses, the researchers traced a rich exchange economy between the anammox bacteria and key partner taxa, notably denitrifiers of the Opitutus genus. The partners traded extracellular polysaccharides, amino acids and essential cofactors, with each group supplying metabolites the other could not synthesize on its own. In effect, the printed material recreated the dense, chemically connected microenvironments of natural biofilms, but with a geometry designed by engineers rather than left to chance.

The performance gains were dramatic. Anammox systems are infamous for their long start-up periods, the slow weeks during which the bacterial community establishes itself before a reactor reaches useful treatment capacity. The printed ELMs cut start-up time by 71.43 percent, a reduction that could translate directly into faster commissioning of full-scale treatment facilities. More importantly, once running, the confined communities achieved complete nitrogen removal, converting ammonium and nitrate all the way to nitrogen gas without the addition of external organic carbon. That last point matters enormously for sustainability, because conventional denitrification requires organic carbon dosing, typically methanol or other electron donors, which adds cost, operational complexity and a carbon footprint of its own. A system that couples anammox to denitrification using internally recycled metabolites sidesteps that requirement entirely.

The study goes beyond engineering demonstration to probe the underlying mechanisms in detail. Metagenomic evidence revealed the genetic basis of the cross-feeding behaviors between AnAOB and Opitutus, showing how spatial confinement reshaped gene content and pathway activity within the community. Non-targeted metabolomics compared the chemical profiles of free anammox consortia and the printed ELMs, documenting the enriched pools of shared metabolites inside the confined structures. Together, these analyses support a coherent picture: the printed architecture does not simply hold cells in place, it actively rewires the metabolic network of the community, favoring mutualistic exchanges over competition and enabling the coupled anammox-denitrification chemistry that has long been the goal of the field.

The broader implications extend across environmental biotechnology and materials science. Engineered living materials are an emerging class of substances in which living cells are embedded within a fabricated matrix, endowing the material with biological functions such as catalysis, sensing or self-repair. Applying this concept to wastewater treatment represents one of its most consequential potential uses, because the scale of the problem is enormous. Nitrogen removal is a major contributor to global energy consumption and greenhouse gas emissions, and the world’s growing cities are generating ever larger volumes of nitrogen-rich sewage. A technology that makes anammox systems start faster, perform better and operate without carbon dosing could meaningfully shrink the environmental footprint of sanitation infrastructure worldwide.

Significant challenges remain before printed living materials flow through municipal treatment plants. The researchers’ experiments were conducted at laboratory scale, and scaling up 3D bioprinting to produce cubic meters of living material, rather than laboratory specimens, will require new manufacturing approaches. The long-term durability of the alginate-cellulose matrix under continuous loading, shear and fluctuating wastewater chemistry must be demonstrated, and the materials must ultimately be retrievable and replaceable within industrial reactors. Regulatory questions about deploying concentrated engineered microbial communities in open infrastructure will also need careful attention. Nevertheless, the study provides what the field has long sought: a viable, mechanistically grounded strategy for the rapid establishment and enhanced performance of anammox systems, validated with real wastewater and grounded in a deep understanding of microbial ecology.

What makes the work resonate beyond its immediate application is the way it reframes the relationship between fabrication technology and biology. For most of industrial history, engineers have built inert structures and asked biology to adapt to them. Here the logic is inverted: the structure is printed around the biology, shaped to amplify the cooperative behaviors that evolution has already written into the microbial genomes. The printed lattice becomes a kind of architectural mediator, translating the metabolic potential of anammox bacteria and their partners into a treatment process that is faster, cleaner and more complete than either organism group could deliver alone. If the approach survives the journey from bench to plant, the humble printed hydrogel may come to be seen as a quiet turning point in humanity’s effort to clean its own water, one layer of living material at a time.

Subject of Research: 3D-bioprinted engineered living materials that couple anammox bacteria and denitrifiers for complete nitrogen removal in wastewater treatment

Article Title: 3D-printed living materials for anammox–denitrification coupling in wastewater treatment

Article References: 3D-printed living materials for anammox–denitrification coupling in wastewater treatment. (n.d.). https://doi.org/10.1038/s41893-026-01921-9

Image Credits: AI Generated

DOI: 10.1038/s41893-026-01921-9

Keywords: anammox, denitrification, 3D bioprinting, engineered living materials, wastewater treatment, nitrogen removal, microbial cross-feeding, spatial confinement, bioink, sodium alginate, metabolomics, environmental biotechnology

Diabetes mellitus is far more than a disorder of blood sugar. Persistent hyperglycemia triggers a slow, systemic assault on tissues throughout the body, and while the kidneys, nerves, and retina receive most of the attention, the spleen quietly suffers as well. This fist-sized lymphoid organ orchestrates innate and adaptive immunity, filters aged red blood cells from circulation, and serves as a critical reservoir of immune cells. When the spleen falters, the consequences ripple outward: anemia worsens, infection susceptibility climbs, and the delicate balance between pro-inflammatory and anti-inflammatory signaling collapses. Earlier studies have documented splenic shrinkage, lymphoid degeneration, and immune dysregulation in diabetic animals, but effective pharmacological protectants remain scarce.

The research team, led by Asma B. Omer of Princess Nourah bint Abdulrahman University together with collaborators across Saudi Arabia, Oman, and India, chose streptozotocin, or STZ, as their diabetes-inducing agent. STZ is a glucosamine-nitrosourea compound that selectively destroys insulin-producing pancreatic beta cells, producing a model of persistent hyperglycemia that closely mirrors the metabolic and oxidative burden of uncontrolled human diabetes. A single intraperitoneal dose of 50 milligrams per kilogram was sufficient to push the Wistar rats into a diabetic state, setting the stage for eight weeks of treatment with oral rufigallol at two doses, 10 and 20 milligrams per kilogram per day.

The baseline damage inflicted by STZ was comprehensive and sobering. Diabetic animals developed sustained elevation of fasting blood glucose alongside a measurable reduction in spleen weight, signaling tissue atrophy. Their hematological profiles deteriorated in a pattern familiar to clinicians: anemia, elevated white cell counts consistent with chronic inflammatory activation, and falling platelet numbers. Beneath these visible changes, the molecular machinery of the spleen was under coordinated attack. Levels of malondialdehyde, a canonical marker of lipid peroxidation, surged, and nitric oxide production climbed, both signatures of unchecked oxidative assault on cellular membranes and proteins.

Equally telling was the collapse of the spleen’s antioxidant shield. Superoxide dismutase, catalase, and reduced glutathione, the enzymatic and non-enzymatic sentinels that normally neutralize reactive oxygen species, were all significantly depleted in the diabetic animals. With antioxidant defenses eroded, the pro-inflammatory cascade gained momentum. The researchers measured markedly increased concentrations of interleukin-1 beta, interleukin-6, tumor necrosis factor-alpha, and interferon-gamma, coupled with suppression of the anti-inflammatory cytokines interleukin-2 and interleukin-4. At the top of this inflammatory hierarchy sat nuclear factor kappa B, NF-κB, the transcription factor that coordinates the expression of dozens of inflammatory genes, and it was strongly activated in the diabetic spleen.

The third prong of the injury was apoptosis, the controlled self-destruction of cells. In the diabetic spleens, the pro-apoptotic protein Bax and the execution enzyme caspase-3 were upregulated, while the anti-apoptotic guardian Bcl-2 was diminished. This shift in the Bax-to-Bcl-2 ratio pushed splenic cells, including the lymphocytes and macrophages that populate the white and red pulp, toward self-elimination. Histopathological examination confirmed the functional data at the tissue level, revealing marked disruption of the normal splenic architecture, with damage to the lymphoid follicles and red pulp structures that underpin the organ’s immune and filtration roles.

Rufigallol treatment turned this grim molecular picture around in a dose-dependent fashion. The higher dose of 20 milligrams per kilogram consistently outperformed the lower dose across nearly every endpoint. Treated animals showed significantly reduced fasting blood glucose, recovered spleen weight, and improved hematological indices, including corrections in the anemia, leukocytosis, and thrombocytopenia that had accompanied the diabetic state. At the biochemical level, the compound restored the depleted antioxidant arsenal, elevating superoxide dismutase, catalase, and glutathione while simultaneously driving down malondialdehyde and nitric oxide, evidence that it both quenched existing oxidative damage and rebuilt the spleen’s capacity to resist it.

The anti-inflammatory and anti-apoptotic effects were equally striking. Rufigallol suppressed the elevated pro-inflammatory cytokines and restrained NF-κB activation, dampening the transcriptional engine of splenic inflammation. At the same time, it rebalanced the apoptotic threshold: Bax and caspase-3 expression fell while Bcl-2 rose, shifting cells away from self-destruction and toward survival. Microscopic analysis of the treated spleens confirmed that these molecular changes translated into tangible structural recovery, with substantially improved preservation of the lymphoid architecture compared with untreated diabetic controls. The authors conclude that rufigallol protected the spleen by simultaneously targeting oxidative stress, inflammatory signaling, and the apoptotic pathway, three interlocking mechanisms that converge on tissue survival.

The choice of rufigallol is scientifically grounded rather than arbitrary. The compound, formally 1,2,3,5,6-pentahydroxy-9,10-anthraquinone, belongs to the anthraquinone family, a class of polyphenolic plant metabolites with a growing resume in metabolic research. Related anthraquinones such as emodin, rhein, and aloe-emodin have shown anti-diabetic, antioxidant, and immunomodulatory properties in prior preclinical studies, and the hydroxyl-rich structure of rufigallol makes it a potent electron donor capable of neutralizing free radicals directly. The polyphenol’s redox activity, the researchers note, aligns with the broader recognition that dietary and plant-derived polyphenols can modulate redox signaling, bioenergetics, and cell fate decisions in ways that synthetic antioxidants often cannot.

The findings carry meaningful implications for a global diabetes epidemic that now affects hundreds of millions of people and continues to expand. Because splenic dysfunction compounds the immune weakness already characteristic of diabetes, contributing to heightened infection risk and poorer vaccine responses, protecting this organ could have clinical value beyond the laboratory. The authors caution that these results derive from a rodent model, and translation to human therapy will require pharmacokinetic profiling, toxicity evaluation, and ultimately controlled clinical trials. Nevertheless, the study adds rufigallol to the short list of natural compounds with demonstrated, mechanistically resolved protection of lymphoid tissue in diabetes, and it strengthens the case that inexpensive plant-derived anthraquinones deserve closer scrutiny as adjunctive agents against the multi-organ toll of chronic hyperglycemia. The research was supported by Princess Nourah bint Abdulrahman University Researchers Supporting Project number PNURSP2026R854.

Subject of Research: Protective effects of the anthraquinone compound rufigallol against streptozotocin-induced splenic injury in diabetic rats

Article Title: Rufigallol attenuates splenic damage caused by STZ by targeting oxidative stress, inflammation, and the apoptosis pathway

Article References: Omer, A. B., Afzal, M., Rafeeq, M., Murad, H. A. S., Alzarea, S. I., Sayyed, N., Kazmi, I., & Al-Abbasi, F. A. (2026). Rufigallol attenuates splenic damage caused by STZ by targeting oxidative stress, inflammation, and the apoptosis pathway. 3 Biotech, 16(10), Article 419. https://doi.org/10.1007/s13205-026-05047-9

Image Credits: AI Generated

DOI: 10.1007/s13205-026-05047-9

Keywords: rufigallol, diabetes, spleen, streptozotocin, oxidative stress, inflammation, apoptosis, NF-κB, anthraquinone, antioxidant, Bcl-2, caspase-3

Enhanced rock weathering has long been touted as one of the most promising carbon removal strategies because it leverages a process that has regulated Earth’s climate for billions of years. When rainwater, slightly acidified by dissolved carbon dioxide, percolates through silicate rocks such as basalt, the carbonic acid pulls calcium and magnesium ions out of the mineral lattice. These ions ultimately combine with carbonate in oceans and soils, forming stable minerals that sequester carbon for tens of thousands of years or longer. The catch is speed: natural weathering operates on geological timescales, and even crushed and spread basalt can take years to decades to absorb a meaningful fraction of the carbon dioxide applied to farmland alongside it.

The new study attacks that bottleneck at its chemical root. Siderophores are small organic molecules with an extraordinary affinity for iron, capable of prizing the metal out of mineral surfaces even at vanishingly low concentrations. In doing so, they destabilize the crystal structures of iron-bearing silicates, exposing fresh surfaces to attack by carbonic and organic acids. Microbiologists have understood this mechanism for decades, but the idea of engineering microbes to produce siderophores at industrial scale for climate purposes remained largely theoretical—until now.

The research team used synthetic biology tools to upregulate the biosynthetic gene clusters responsible for siderophore synthesis in their bacterial strain, carefully balancing the metabolic burden that enhanced production imposes on the cells. Overproducing secondary metabolites can cripple microbial growth, so the engineering had to thread a needle between maximizing output and keeping the organisms viable. The resulting strains secreted siderophore concentrations several times higher than wild-type counterparts, and when applied to crushed basalt in controlled experiments, the treated microbial communities accelerated mineral dissolution rates well beyond what natural weathering achieves.

Measurements of dissolved ions released from the rock confirmed that the engineered bacteria were genuinely driving enhanced weathering rather than simply growing more prolifically. Elevated concentrations of calcium, magnesium, and silicon in solution served as chemical fingerprints of accelerated mineral breakdown. The researchers also tracked the fate of the released cations, which are the direct precursors of the carbonate species that permanently store carbon dioxide, providing a quantitative link between microbial activity and the theoretical carbon removal potential of the system.

What makes the approach especially attractive is its compatibility with existing agricultural practice. Enhanced rock weathering proposals typically involve spreading crushed basalt—a byproduct of mining and quarrying industries—across croplands, where it can also supply nutrients and raise soil pH. Adding engineered bacteria or their siderophore products to this workflow requires no new land, no exotic infrastructure, and no dramatic change in farm operations. The biological catalyst simply boosts the yield of carbon removal per tonne of rock applied, improving the economics of a scheme whose costs have otherwise been dominated by the grinding and transport of stone.

The carbon math is compelling if the laboratory results translate to the field. A single tonne of basalt can, in principle, absorb on the order of hundreds of kilograms of carbon dioxide over its weathering lifetime. If microbial siderophores can compress that timeline or increase the fraction of rock that fully dissolves, the effective carbon removal capacity of each tonne of applied rock rises accordingly, and with it the viability of gigatonne-scale deployment scenarios that climate models suggest will be necessary alongside deep emissions cuts.

Significant hurdles remain before engineered weathering microbes see real-world deployment. Field soils are wildly heterogeneous environments where introduced strains face competition from established microbial communities, predation, and fluctuating moisture and temperature. Regulators will also demand rigorous assessment of any genetically modified organism released into open agricultural systems, and researchers will need containment strategies or self-limiting designs to address ecological concerns. The team acknowledges that scaling from petri dishes and reactor columns to windswept fields is the defining test ahead.

Still, the study marks a striking convergence of biotechnology and geoscience, suggesting that the tools of synthetic biology can be pointed not merely at medicines and materials but at the planet’s own climate-regulating chemistry. If follow-up field trials vindicate the laboratory findings, the humble bacterial molecules that microbes have used for eons to feed on rock-bound iron could become one of the cheapest levers available for scrubbing carbon dioxide from the sky—and a vivid reminder that some of the most powerful climate technologies may already be alive in the soil beneath our feet.

Subject of Research: Engineered bacterial siderophore production for enhanced silicate rock weathering and carbon dioxide removal

Article Title: Engineered bacterial siderophore production accelerates rock weathering for carbon removal

Article References: Dalvie, N. C., Jalihal, A. P., Fitzgibbon, A., Böhnke, J.-T., Hijaz, M., Justman, Q. A., Davis, S. J., Silver, P. A., & Springer, M. (2026). Engineered bacterial siderophore production accelerates rock weathering for carbon removal. Nature Biotechnology. https://doi.org/10.1038/s41587-026-03288-w

Image Credits: AI Generated

DOI: 10.1038/s41587-026-03288-w

Keywords: enhanced rock weathering, siderophores, carbon removal, synthetic biology, basalt, silicate minerals, carbon dioxide sequestration, soil microbiology, climate engineering, mineral dissolution, biogeochemistry, Nature Biotechnology

The distinction is more than taxonomic housekeeping. Liquid-phase vesicles, which have fuelled a decade of biomarker discovery and therapeutic development, are subject to dilution, clearance and non-specific biodistribution the moment they enter circulation. Matrix-bound vesicles, by contrast, never leave home. They stay tethered to the fibrous network of collagen, glycoproteins and other macromolecules that gives tissue its structure, delivering their cargo of proteins, lipids and microRNAs to neighbouring cells in a strictly local, context-dependent manner. In doing so, they function not merely as passengers within the matrix but as functional components of it, shaping tissue development, regeneration and day-to-day homeostasis.

The technical case for treating matrix-bound vesicles as a separate population rests on molecular evidence. Lipidomic and RNA sequencing studies of vesicles extracted from decellularized extracellular matrix bioscaffolds have revealed cargo profiles that differ measurably from those of vesicles harvested from the surrounding fluid. Proteomic comparisons of liquid-phase and matrix-bound vesicles grown in both two-dimensional and three-dimensional cell cultures reinforce the picture of two biochemically distinct populations. Matrix-bound vesicles carry tissue-specific protein and microRNA signatures, suggesting that they act as regulatory components of the matrix rather than as incidental debris trapped in its fibres.

That tissue specificity is one of the most striking features of the new framework. Vesicles isolated from decellularized cardiac, skeletal muscle, bone and other tissues recapitulate the angiogenic and immunomodulatory properties of their parent matrices, and their microRNA profiles differ from tissue to tissue. In bone, matrix vesicle cargo such as the microRNA miR-125b accumulates within the mineralized matrix and inhibits bone resorption in mouse models. In skeletal muscle, vesicle-associated interleukin-33 has been shown to initiate a pro-regenerative shift in macrophage phenotype after injury, supporting functional recovery. The vesicles, in effect, carry a molecular record of the tissue they came from—and a set of instructions appropriate to that tissue.

The review also documents how this record changes with age and disease, and the implications are unsettling. Studies of aged breast tissue show that matrix-bound vesicles from older matrices carry cargo that promotes invasiveness in breast epithelial and cancer cells, suggesting that the aged microenvironment itself can actively contribute to tumour progression. Cardiac tissue-resident vesicles regulate fibroblast activation in an age- and sex-dependent manner, and multi-omics profiling of young and aged plasma and matrix-bound vesicles has identified anti-fibrotic microRNAs enriched in the young versions, with therapeutic activity validated in a heart-on-a-chip model. In colorectal cancer, vesicles trapped in decellularized tumour matrix preserve disease-associated signatures of the tumour microenvironment, while cancer-associated fibroblasts have been shown to produce matrix-bound vesicles that influence endothelial cell function. The matrix, in other words, is not a passive scaffold but an active archive of pathological state.

Therapeutically, the localized nature of matrix-bound vesicles is both their greatest asset and their central challenge. Because they act where they are placed, they are natural candidates for integration into engineered tissues and biomaterial delivery platforms. Matrix-bound vesicles embedded in cartilaginous extracellular matrix have enabled functional reconstruction of tracheal defects, vesicles from decellularized tumours have been used as platforms for targeting parent tumour cells and tumour-associated stromal cells, and injectable microsphere systems are being developed for sustained delivery in adipose tissue engineering. Immunomodulatory matrix-bound vesicles derived from urinary bladder matrix have mitigated influenza-mediated lung inflammation while preserving antiviral responses, eased rheumatoid arthritis in preclinical models, and alleviated particulate-induced periprosthetic osteolysis. Recent work even suggests these vesicles can accumulate in bone marrow and induce durable epigenetic changes in myeloid progenitors and macrophages, hinting at effects that outlast the vesicles themselves.

Compared with their liquid-phase cousins, matrix-bound vesicles may also sidestep some of the biodistribution problems that have plagued systemic vesicle therapies. Circulating vesicles must survive the bloodstream, cross vascular barriers and find the right tissue before releasing their cargo, and much of the dose is lost along the way. A vesicle pre-positioned within an implanted scaffold or hydrogel faces no such gauntlet. The trade-off is that delivery becomes inseparable from the biomaterial itself: the scaffold must retain the vesicles, present them to infiltrating host cells and release them, if release is desired, on a controlled schedule. This couples vesicle therapy directly to the maturing field of engineered extracellular matrices, decellularized scaffolds and bioprinted tissues.

Getting there, the authors caution, requires solving problems that the liquid-phase vesicle field has only partially addressed. Isolation of matrix-bound vesicles depends on decellularization protocols whose harshness can alter yield, purity and function, and different isolation methods produce vesicles with different biological behaviour. Characterization remains hampered by the heterogeneity of vesicle populations and by the lack of standardized reporting, although community frameworks such as the MISEV guidelines are pushing the field toward rigor. Downstream, translating cargo profiles into diagnostics or therapeutics will demand bioinformatics integration across proteomics, lipidomics and transcriptomics, and manufacturing clinical-grade material will require scalable, validated processes. The review singles out innovations in isolation, characterization, bioinformatics and bioengineered delivery as the four pillars on which translational success will rest.

What emerges from the analysis is a reframing of how biologists should think about the space between cells. The extracellular matrix has long been appreciated as a mechanical and structural environment that influences stem cell fate, angiogenesis and fibrosis. The new work positions matrix-bound vesicles as the signalling layer of that environment—a distributed, tissue-encoded communication network that operates alongside, and distinct from, the systemic vesicle traffic carried in blood, urine, saliva and other biofluids. If the framework holds, diagnostics could one day read the vesicular archive embedded in a biopsy or decellularized scaffold to reconstruct a tissue’s recent history, and regenerative therapies could seed engineered implants with vesicles pre-loaded with the molecular instructions a healing tissue needs. The quiet postal service in the matrix, long overlooked, may prove to be one of the most consequential mail routes in the body.

Subject of Research: Matrix-bound extracellular vesicles as tissue-specific, matrix-anchored mediators of local intercellular signalling in health, ageing and disease

Article Title: Matrix-bound extracellular vesicles

Article References: Matrix-bound extracellular vesicles. (n.d.). https://doi.org/10.1038/s44222-026-00477-9

Image Credits: AI Generated

DOI: 10.1038/s44222-026-00477-9

Keywords: extracellular vesicles, matrix-bound vesicles, extracellular matrix, tissue engineering, regenerative medicine, biomarkers, microRNA, decellularization, immunomodulation, tumour microenvironment, drug delivery, Nature Reviews Bioengineering

Standard organoid culture media typically include a basal formulation such as DMEM/F12 supplemented with factors that promote neural differentiation, including N2 and B27 supplements, and often retinoic acid at later stages to encourage photoreceptor maturation. Variations among laboratories in the choice of basal medium, the concentration of supplements, the presence or absence of serum components, and the timing of factor additions have long been recognized as sources of heterogeneity, but the systematic consequences of these choices for downstream applications have been less thoroughly characterized. The finding that media alter both adeno-associated virus transduction and retinal ganglion cell survival suggests that seemingly minor formulation differences can propagate into functional outcomes that matter enormously for translational work.

Adeno-associated virus vectors are the leading platform for retinal gene therapy, with approved products demonstrating that subretinal or intravitreal delivery can produce durable clinical benefit in inherited retinal degenerations. The success of AAV-mediated gene transfer depends on a cascade of events: vector particles must reach the target cells, bind to cell surface receptors, undergo endocytosis, traffic through the cytoplasm, enter the nucleus, uncoat, and convert their single-stranded genome into a transcriptionally competent double-stranded form. Each step can be influenced by the physiological state of the target cell, including membrane composition, endosomal trafficking dynamics, proteasome activity, and the expression of factors that second-strand synthesis. If culture media shift cells into states that favor or hinder any of these steps, then organoid-based assessments of vector tropism and potency will yield results that are artifacts of the culture condition rather than faithful predictions of clinical behavior.

This consideration is particularly acute because organoids are increasingly used as preclinical screening platforms for vector engineering. Researchers seeking capsids with improved photoreceptor tropism, or with the ability to penetrate the inner limiting membrane after intravitreal injection, frequently validate their designs in retinal organoids before advancing to animal studies. A capsid that appears highly efficient in organoids maintained in one medium might underperform in organoids maintained in another, not because the capsid has changed but because the cellular context has. Standardizing media composition, or at minimum reporting it comprehensively and testing key findings across multiple formulations, would strengthen the predictive value of such screens and reduce the risk of pursuing vector designs whose apparent advantages do not survive a change of culture conditions.

The effects on retinal ganglion cell survival are equally consequential. Retinal ganglion cells are the projection neurons of the visual system, conveying visual information from the retina to the brain through the optic nerve, and their degeneration underlies glaucoma and other optic neuropathies. In organoid culture, ganglion cells are notoriously fragile; they are among the first cell types generated, they reside in the innermost layer of the tissue, and they depend on trophic support that is difficult to reproduce in a dish. Their progressive loss during long-term organoid culture is a well-documented limitation, and it complicates any effort to model ganglion cell diseases or to test neuroprotective strategies. If specific medium components can substantially extend ganglion cell survival, this opens two important avenues: first, the creation of longer-lived organoid models in which disease-relevant cell types remain available for study; and second, the identification of the trophic factors and metabolic conditions that ganglion cells require, which may themselves point toward therapeutic targets.

The mechanistic links between medium composition and cell survival likely involve several intersecting pathways. Oxidative stress is a prominent candidate, since retinal neurons are metabolically demanding and vulnerable to reactive oxygen species, and the antioxidant capacity of medium supplements such as those in B27 varies with formulation and with the degradation of components over time in culture. Energy metabolism is another: the retina is among the most oxygen-consuming tissues in the body, and photoreceptors in particular rely on aerobic glycolysis, a metabolic mode whose support depends on glucose and pyruvate availability in the medium. Growth factor signaling, including pathways involving BDNF, CNTF, GDNF, and insulin-like growth factors, also modulates ganglion cell survival, and the presence, stability, and concentration of such factors differ across media formulations. Even the buffering system and the resulting pH stability can influence neuronal health, as can osmolarity and the accumulation of metabolic waste products between medium changes.

For AAV transduction specifically, medium composition might act through effects on the cell surface. The glycocalyx, the dense layer of sugars coating the plasma membrane, provides attachment points that many AAV seruses exploit, and its composition is sensitive to culture conditions, including the availability of specific sugars and the activity of glycosyltransferases. Heparan sulfate proteoglycans serve as primary attachment receptors for several AAV serotypes, and sialic acid residues are critical for others. Media that alter glycosaminoglycan synthesis or sialylation could therefore change the efficiency of the initial binding step. Downstream, intracellular trafficking depends on the cytoskeleton and on endosomal pH, both of which can be modulated by medium components such as ammonium chloride accumulation, chloroquine-like compounds, or simply the energetic state of the cell. These mechanisms offer plausible, testable explanations for how the same vector applied to the same organoid type can perform differently across media.

The broader lesson resonates with a recurring theme in stem cell biology: the environment is part of the experiment. Organoids are often described as miniaturized versions of human tissues, but they are better understood as products of a continuous dialogue between intrinsic developmental programs and the culture environment. Small differences in oxygen tension, media exchange schedules, matrix composition, and the physical handling of cultures have all been shown to affect organoid morphology and cell type composition. The present findings add media formulation to this list in a way that directly touches two of the most translationally important readouts: gene delivery efficiency and survival of a clinically critical neuron.

From a practical standpoint, laboratories working with retinal organoids for gene therapy applications should consider several measures. Detailed documentation of medium composition, including lot numbers of supplements whose activity varies between batches, would improve reproducibility across the field. Cross-validation of key results in at least two distinct media formulations would reveal whether findings are robust or condition-dependent. Where possible, matching the metabolic and trophic environment of the organoid to the physiological state of the target tissue in vivo would improve the clinical relevance of preclinical testing. For ganglion cell studies specifically, optimizing media for survival may need to be balanced against the goal of photoreceptor maturation, since conditions that favor one cell class may not favor another, and the developmental timing of these requirements may differ.

There are also implications for disease modeling. Many inherited retinal diseases are cell-type specific, and the value of an organoid model depends on maintaining the relevant cells in a state that resembles their in vivo counterpart. Ganglion cell loss in culture has limited the use of organoids for modeling optic neuropathies such as those caused by mutations in OPA1 or other genes affecting mitochondrial function. If optimized media extend ganglion cell survival substantially, models of these diseases become feasible, enabling the study of pathogenesis in a human developmental context and the screening of candidate neuroprotective compounds. Similarly, for glaucoma research, where the interplay between elevated intraocular pressure, axonal transport disruption, and somal survival is difficult to disentangle in animal models, longer-lived organoid systems with robust ganglion cell populations would provide a complementary human platform.

The intersection with AAV biology deserves particular attention as the gene therapy field matures. Dose-limiting toxicity, immune responses, and the challenge of achieving pan-retinal transduction after intravitreal delivery remain central obstacles. Organoids offer a human-relevant system in which to evaluate candidate capsids, promoters, and expression cassettes, but their utility depends on the transduction results reflecting what would occur in a patient retina. The finding that media promote or suppress transduction suggests that part of the variability reported across organoid studies of AAV tropism may be attributable to culture conditions rather than to genuine differences in vector performance. Disentangling these variables will require systematic comparisons in which identical vectors are applied to organoids raised in parallel under different media conditions, with careful quantification of both transduction efficiency and the cell-type composition of the tissues.

It is also worth considering how these findings fit into the larger regulatory and manufacturing landscape. As retinal organoids move toward use in potency assays and release testing for cell and gene therapy products, the dependence of their properties on media composition becomes a matter of product consistency. Regulatory frameworks emphasize the characterization of critical quality attributes, and for organoid-based assays, the culture medium is arguably a critical reagent whose composition must be controlled with the same rigor as the biological material itself. Manufacturers of media and supplements may need to provide more detailed specifications, and users may need to implement qualification procedures for each new lot, particularly for supplements such as B27 whose complex composition includes components with variable biological activity.

Looking forward, the systematic mapping of how individual medium components affect retinal organoid physiology could yield a design framework for culture conditions tailored to specific applications: media optimized for photoreceptor maturation for studies of inherited photoreceptor degenerations, media optimized for ganglion cell survival for optic neuropathy models, and media that support efficient AAV transduction for vector validation studies. Such an approach would treat the medium as an engineering variable rather than a fixed convention, transforming a source of uncontrolled variability into a tool for shaping organoid properties. The present work, by demonstrating that culture media alter both AAV transduction and retinal ganglion cell survival in retinal organoids, provides both a caution about the interpretation of existing organoid studies and a constructive starting point for this more deliberate approach to organoid culture design.

Subject of Research: Culture media alter retinal organoid physiology promoting AAV transduction and retinal ganglion cell survival

Article Title: Culture media alter retinal organoid physiology promoting AAV transduction and retinal ganglion cell survival

Article References: O’Hara-Wright, M., Lim, B. Y., M. Mangala, M., Kaiser, V., Wong, E., Aubin, D., Nemeruck, V., Reynisson, H., Doroudian, F., Chan, O. P. Y., Aryamanesh, N., A. Paulo, J., Palomba, S., Mirzaei, M., Ginn, S. L., & Gonzalez-Cordero, A. (2026). Culture media alter retinal organoid physiology promoting AAV transduction and retinal ganglion cell survival. Gene Therapy. https://doi.org/10.1038/s41434-026-00642-0

Image Credits: AI Generated

DOI: 10.1038/s41434-026-00642-0

Keywords: Culture, media, alter, retinal, organoid, physiology, promoting, transduction, ganglion, cell, survival, scientific research

The stakes could hardly be higher. The endometrium sits at the centre of embryo implantation, pregnancy maintenance and broader reproductive and systemic health, yet conditions affecting it—endometriosis, adenomyosis, recurrent implantation failure, recurrent pregnancy loss and chronic endometritis—remain poorly understood and notoriously difficult to treat. The authors argue that the root of this knowledge gap lies in the tools the field has historically depended upon: animal models and two-dimensional cultures that systematically fail to reproduce the human endometrium’s intrinsic biology.

The problem with animal models begins with basic evolutionary divergence. Mice, the workhorse of biomedical research, do not menstruate, and their endometrial architecture, hormone responsiveness and decidualization programmes—divided into the stem-cell-rich basalis that regenerates the tissue each cycle and the functionally active functionalis that is shed during menstruation—differ in fundamental ways from those of humans. Even the spiny mouse, the only rodent known to menstruate, offers only a partial bridge. Baboons show spontaneous endometriosis, making them useful but expensive and ethically constrained. The review details how comparative studies between human and rat endometrial co-cultures have repeatedly exposed these species-specific gaps, underscoring why findings from mice frequently fail to translate into human clinical practice.

Two-dimensional cell culture, meanwhile, has its own structural limitations. Landmark studies dating back to the early twentieth century established the foundations of tissue culture, and endometrial research made enormous strides with immortalized cell lines such as Ishikawa and HEC-1 adenocarcinoma-derived cells, alongside primary cultures of endometrial epithelial glands and stromal cells isolated as early as the 1970s. These systems enabled researchers to dissect steroid metabolism, integrin expression, 17 beta-hydroxysteroid dehydrogenase regulation and paracrine signalling between epithelium and stroma. Yet flat monolayers strip away the three-dimensional geometry, cell polarity, extracellular matrix interactions and multicellular composition that define how the endometrium actually behaves—particularly during the precisely timed window of implantation, when epithelial polarity shifts and stromal cells undergo decidualization under progesterone control.

The inflection point arrived in 2017, when two independent teams grew long-term, hormone-responsive organoids from human endometrium in chemically defined media. These miniature, self-organizing structures, built from endometrial epithelial stem and progenitor cells, recapitulated key features of endometrial physiology, expanded over successive passages and responded to oestrogen and progesterone much as the native tissue does. Suddenly, researchers could grow living endometrial epithelium indefinitely, derive it from patients with disease, and interrogate its biology with genetic and pharmacological tools. Follow-up work showed that patient-derived organoids could capture clinical heterogeneity in endometrial disease and were amenable to drug screening—opening a genuine pathway toward personalized medicine in gynaecology.

The next generation of models has pushed further toward physiological realism. Multi-lineage assembloids now combine endometrial epithelium with stromal fibroblasts, immune components, endothelial cells and extracellular matrix in engineered assemblies that mimic the tissue’s natural architecture. Recent protocols for generating mouse and human endometrial assembloids allow epithelial–stromal crosstalk to be studied within a single three-dimensional construct, while air–liquid interface methods have yielded assembloids possessing a luminal epithelium—the very surface a blastocyst must breach during implantation. Studies using assembloids have already modelled how decidual senescence impairs embryo implantation and how adenomyosis-related endometrial receptivity is compromised, delivering mechanistic insights that flat cultures simply could not provide.

Bioengineering has multiplied these capabilities. Microfluidic endometrium-on-a-chip devices compartmentalize perivascular stroma and endothelial cells to create vascularized tissue architectures, and experiments within them have shown that hemodynamic forces enhance decidualization via endothelial-derived prostaglandin E2 and prostacyclin—demonstrating that mechanical cues from blood flow, absent in static cultures, are genuine regulators of endometrial function. Fully synthetic hydrogels have replaced animal-derived Matrigel in several systems, enabling precise control of matrix composition and permitting organoid co-cultures of epithelium and stroma to be studied in defined extracellular environments. Bioprinted, hormone-responsive bilayer models now reproduce the tissue’s layered structure, and engineered platforms incorporating a 28-day hormonal cycle have simulated the human menstrual cycle in vitro, capturing epithelial cell transitions during menstruation and regeneration.

Perhaps the most consequential frontier is implantation itself. Because direct observation of human embryo implantation is ethically impossible, the field has had to infer its mechanics from indirect evidence. That barrier is now falling. Stem-cell-derived blastoids and trophoblast organoids can be co-cultured with engineered endometrial models to recreate the first contact between embryo and maternal tissue. Recent studies have modelled the embryo–endometrial interface in three dimensions, produced human receptive endometrial assembloids designed to decode the implantation window, and developed microfluidic platforms that measure embryo adhesion in real time. The review highlights 2026 studies reporting three-dimensional post-implantation co-culture of human embryo and endometrium models, alongside paired investigations of implantation and implantation failure—work that together promises to reveal the molecular dialogue between embryo and mother at unprecedented resolution. Single-cell atlases of the endometrium and the maternal–fetal interface, including a recently published spatiotemporal dissection of the human maternal–fetal interface, are providing the reference maps against which these engineered systems can be validated.

The clinical implications radiate across women’s health. Endometriosis, a chronic systemic disease affecting an estimated one in ten women of reproductive age, has seen its cellular basis illuminated by single-cell transcriptomic studies of eutopic and ectopic tissue, multi-ancestry genome-wide association analyses and investigations of microRNA signatures in tissue, serum and extracellular vesicles—several of which show promise as non-invasive diagnostic biomarkers. Patient-derived organoids from endometriosis lesions and early peritoneal endometriosis models now allow drug testing on a patient’s own disease cells. Endometrium-on-chip platforms built from patient cells are being evaluated for assessing endometrial receptivity and guiding personalized fertility treatment, while recent organoid work has even traced the donor-derived cellular origin of endometrium after uterus transplantation. Insulin- and glucose-induced alterations in endometrial transcriptomes observed on-chip hint at mechanisms linking metabolic health to fertility, and scaffold-free organoids have been shown to respond to the excess androgens characteristic of polycystic ovarian syndrome.

The authors are candid that substantial challenges remain. Matrigel, the tumor-derived basement membrane matrix underpinning many organoid protocols, is chemically undefined and variable, motivating ongoing efforts to develop fully synthetic alternatives. Vascularization, immune cell incorporation and the biophysical environment of the uterus—contractions, blood flow, cyclic mechanical remodeling—are only partially captured by existing systems. Ethical governance is advancing alongside the science: revised international stem cell guidelines now specifically address stem-cell-based embryo models, and frameworks for embedded ethics and dynamic consent are being proposed for research that grows ever closer to reconstructing human development in a dish. Competition-of-interest disclosures and peer oversight remain part of the field’s infrastructure as its translational potential grows.

What emerges from this sweeping synthesis is a portrait of a field in the midst of a genuine paradigm shift. By uniting developmental biology, stem-cell science, tissue engineering and single-cell genomics, researchers are converging on engineered endometria that are hormone-responsive, multicellular, vascularized and patient-specific. Such systems could transform how infertility is diagnosed, how endometriosis is treated and how the safety of new therapeutics is tested—without recourse to animal models that so often mislead. More profoundly, they are rewriting what it means to understand human reproduction: replacing inference from mice with direct observation in human-like tissue, and giving clinicians, for the first time, a living laboratory in which the earliest events of human life can be watched, perturbed and, ultimately, protected.

Beyond implantation, the cyclical nature of the endometrium itself presents a modelling challenge that these new platforms are beginning to address. Unlike most human tissues, the endometrium undergoes scarless repair after each menstrual shedding, a process driven by adult stem and progenitor cells residing in the basalis. Organoid systems that sustain long-term expansion now allow this regenerative capacity to be examined directly, complementing single-cell reference atlases that have catalogued the tissue’s cellular diversity across the menstrual cycle.

The immune dimension is equally critical. Uterine natural killer cells and other maternal immune populations orchestrate fetal–maternal tolerance and guide the differentiation of invading trophoblast, yet most current models lack immune components entirely. Integrating these lineages into assembloids and chip platforms remains an active area of development, informed by single-cell reconstructions of the maternal–fetal interface.

For patients, the promise is tangible: organoids derived from diseased tissue preserve the molecular signatures of the individual they came from, enabling drug responses to be tested outside the body. As these models mature, they may reduce reliance on both animal experimentation and empirical trial-and-error in fertility clinics, offering a mechanistic bridge between a patient’s cellular biology and her clinical care.

Subject of Research: Bioengineered three-dimensional models of the human endometrium, including organoids, assembloids and microfluidic devices, for studying implantation, endometrial disease and personalized reproductive medicine.

Article Title: Engineering the human endometrium at the intersection of development and reproduction

Article References: Vélez-Avilés, A. N., Abel, A., Taylor, H. S., & Sozen, B. (2026). Engineering the human endometrium at the intersection of development and reproduction. Nature Biomedical Engineering. https://doi.org/10.1038/s41551-026-01789-2

Image Credits: AI Generated

DOI: 10.1038/s41551-026-01789-2

Keywords: human endometrium, organoids, assembloids, endometrium-on-a-chip, embryo implantation, endometriosis, tissue engineering, decidualization, stem cells, women's health, single-cell transcriptomics, personalized medicine

The search for microbes capable of breaking down petroleum is far from academic. Petroleum hydrocarbons are among the most stubborn and widespread soil pollutants on the planet, released through refinery operations, pipeline leaks, storage failures and spills. Traditional remediation—digging up and incinerating contaminated soil, or washing it with chemical solvents—is expensive, disruptive and energy-intensive. Bioremediation, in which living organisms metabolize the pollutants into simpler compounds, promises a gentler, cheaper and more sustainable alternative. But its success hinges on finding the right organisms: microbes that not only tolerate the toxic cocktail of a petroleum spill but actively consume it. Increasingly, researchers argue that the best candidates come from the very sites they are meant to clean, because these indigenous strains are already adapted to local chemistry, temperature and salinity.

That logic drove the Algerian team’s sampling strategy. From petroleum-contaminated soils and petroleum products collected in Algeria, they recovered twelve distinct isolates and set out to identify them precisely. Bacterial strains were characterized by sequencing their 16S rRNA genes—the standard molecular barcode for bacteria—while the fungal isolate was identified by sequencing the internal transcribed spacer (ITS) region, the analogous barcoding region for fungi. Phylogenetic analysis placed the isolates within familiar and ecologically meaningful genera: Bacillus, Micrococcus, Enterococcus, Kocuria, Pseudomonas, Streptomyces, Aneurinibacillus and Lysinibacillus among the bacteria, and Aspergillus among the fungi. These genera recur repeatedly in hydrocarbon biodegradation studies worldwide, a sign that the Algerian sites share microbial players with contaminated environments on other continents.

The first screen was deceptively simple: could each isolate grow in a mineral salt medium—essentially water, salts and nothing else—with diesel or gasoline supplied as the sole added organic carbon source? Any growth observed under these conditions means the microbe must be extracting energy and carbon from the fuel itself. All twelve isolates passed this test, but with strongly strain- and substrate-dependent responses. Growth was tracked by optical density at 600 nanometers (OD600), a standard spectrophotometric proxy for cell density. Bacillus sp. strain K2 posted the highest diesel-associated biomass accumulation, reaching an OD600 of roughly 1.9, while Micrococcus sp. strain K8 and the filamentous fungus Aspergillus sp. strain K12 were the strongest performers on gasoline, each exceeding an OD600 of 1.3. The differences between strains on the same fuel—and the differences each strain showed between diesel and gasoline—underscore a key point in bioremediation planning: the choice of candidate microbe must match the specific contaminant mixture on site.

Growth, however, is only part of the story. Petroleum hydrocarbons are poorly soluble in water and tend to cling tightly to soil particles, making them physically inaccessible to microbial enzymes. Many oil-degrading microbes solve this problem by producing biosurfactants—molecules that lower surface tension, emulsify oily droplets and mobilize hydrocarbons so they can be more readily attacked. The team probed this surface-active potential with three complementary assays. Nine of the twelve isolates showed measurable emulsification activity. Enterococcus sp. strain K1 achieved an emulsification index of approximately 29 percent with diesel, while Kocuria sp. strain K3 reached approximately 39 percent with gasoline. Every isolate, moreover, produced a positive drop-collapse response. In this rapid screening test, a droplet of hydrocarbon is placed on a surface and culture is added; if extracellular surfactants are present, the droplet’s surface tension collapses and it spreads flat. A positive result across the board suggests that surface-active behavior is a common strategy in this microbial community.

The third assay probed a subtler property: cell surface hydrophobicity, measured using the Microbial Adhesion To Hydrocarbons (MATH) method. In MATH, a suspension of cells is mixed with a hydrocarbon phase; the fraction of cells that migrate into the hydrocarbon layer reflects how hydrophobic their surfaces are. Hydrophobic cell surfaces promote direct contact with oil droplets, which can enhance uptake of hydrocarbons without the need for extensive surfactant production. The results ranged dramatically—from 18 to 79 percent with diesel and from 4 to 65 percent with gasoline—depending on both the strain and the fuel. Pseudomonas sp. strain K4 showed the highest diesel-associated hydrophobicity, and Streptomyces sp. strain K9 the highest with gasoline. The wide spread suggests that different isolates have evolved different strategies for getting at their oily food, from emulsification to direct surface attachment.

The decisive test came in soil microcosms: small, controlled vessels of sterilized soil spiked with fuel and inoculated with individual strains. Rather than attempting to track every individual hydrocarbon molecule, the researchers measured operational bulk hydrocarbon removal, extracting residual hydrocarbons from the soil with solvents and quantifying them by ultraviolet–visible (UV–Vis) spectrophotometry. The results were striking. Aneurinibacillus sp. strain K7 removed 76.08 percent of the diesel under the assay conditions, while Lysinibacillus sp. strain K10 achieved 91.32 percent removal with gasoline—the highest figure in the entire study. For a simple screening pipeline built entirely from locally sourced isolates, those numbers represent a substantial proof of concept: native microbes from Algerian contaminated sites can eliminate the great majority of measurable fuel hydrocarbons, at least in sterilized laboratory soil.

The authors are careful, and rightly so, about what these numbers do and do not mean. Bulk removal by UV–Vis is an operational measure, not a detailed chemical assay. It confirms that the quantity of UV-absorbing hydrocarbons declined; it does not by itself prove that every compound was fully mineralized to carbon dioxide and water, nor does it reveal which specific hydrocarbon fractions—alkanes, aromatic compounds, branched chains—were attacked and which persisted. Polycyclic aromatic hydrocarbons, in particular, are more toxic and more resistant to biodegradation than straight-chain alkanes, and their fate must be tracked with compound-specific techniques such as gas chromatography–mass spectrometry before any environmental claim can be made. Similarly, the chemical identity of the surface-active molecules—whether glycolipids, lipopeptides or polymeric biosurfactants—remains uncharacterized, as does their potential toxicity.

There is also a safety dimension. The isolates were selected for their ability to live with fuels, not for their friendliness to humans or ecosystems. Any field deployment of live microbes requires a biosafety assessment: confirming that strains are non-pathogenic, that they do not carry antibiotic resistance genes likely to spread, and that they behave predictably when released into complex, unsterilized soils populated by their own competitors and predators. The use of sterilized soil in the microcosms, while necessary for a clean comparison among strains, deliberately sidesteps the messy ecology of a real spill site. Field performance could be better or worse depending on nutrient availability, soil texture, moisture, temperature and interactions with resident microbes.

Even with those caveats, the study offers a template that other regions can follow. Its strength lies in the multi-assay screening logic itself: rather than betting on a single laboratory metric, the team combined growth assays, emulsification tests, drop-collapse screening, MATH hydrophobicity measurements and soil microcosm removal into a single decision framework. Notably, the microcosm champions were not always the growth or emulsification champions, which validates the approach of testing multiple traits independently. A strain like Lysinibacillus sp. K10 might never have stood out on a growth curve alone, yet it delivered the most impressive gasoline removal in soil. Conversely, Bacillus sp. K2’s vigorous diesel growth did not translate into the top diesel removal figure.

The findings also carry local significance for Algeria, an oil and gas producer where petroleum contamination is a persistent environmental concern. Indigenous isolates adapted to North African soils and climates may hold practical advantages over generic inoculants imported from elsewhere—better survival, better competition and better seasonal performance. And the diversity recovered from just twelve isolates hints at a much larger reservoir of hydrocarbon-metabolizing diversity still waiting in these soils, including consortia in which complementary strains might degrade different fractions of a fuel mixture simultaneously.

The next steps, the researchers indicate, are compound-specific hydrocarbon profiling to see exactly which molecules disappear, chemical characterization of the surface-active metabolites to identify potential biosurfactants, and formal biosafety evaluation of the leading strains. If those hurdles are cleared, the path leads toward greenhouse trials and, eventually, field-scale bioaugmentation—inoculating contaminated land with purpose-chosen native microbes. In a world littered with the residues of a century of oil, the idea that the best cleanup crew may already be living in the dirt is an appealing one. This study shows it is more than an idea; it is measurable, strain by strain, drop by collapsed drop, down to 91 percent of a tank of gasoline dissolved into soil by a bacterium with an unassuming name.